US online forum BioSpace reports Noxopharm's announcement, " Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting 'Cold' Tumors to 'Hot'.
Click here to read more.
US publication Clinical Research News: the Industry Updates section mentions Noxopharm's planned COVID-19 trial using Veyonda®.
Genetic Engineering and Biotechnology News (GEN): reports on Noxopharm's Veyonda® as a potential COVID-19 treatment candidate, noting it as a cGAS-STING signaling pathway inhibitor designed to treat the cytokine storm and septic shock associated with COVID-19.
CenterWatch Weekly notes in its COVID-19 Drug Research Roundup - Therapeutics : Noxopharm has begun planning a phase 1 trial of its investigational oncology drug Veyonda(NOX66) in Europe.
In more industry news, Pharmaceutical Business Review (UK) highlighted that Noxopharm reports its COVID-19 trial programme planned to commence a Phase 1 trial in Europe.
US biotech publication BioWorld highlights Noxopharm’s idronoxil’s ability to block the STING pathway in a potential treatment in the fight against COVID-19.
Noxopharm announcement that scientific data from DARRT-1 and LuPIN prostate cancer treatment studies included in two major oncology conferences this year, as covered by Biotech Dispatch
Australian drug development company Noxopharm™ to present interim results on new prostate cancer treatment at specialist oncology conferences in Australia and overseas
US digital medical magazine Healthcare Tech Outlook profiling the enhancing effect of Veyonda on radiotherapy seen in pre-clinical trials and in clinical trials with men with prostate cancer.
AddressLevel 4, 828 Pacific Highway Gordon. 2072 NSW AUSTRALIA
PO Box 292, Gordon
2072 NSW AUSTRALIA
50 608 966 123
Join our mailing list to receive the latest information from Noxopharm Limited